Carboplatin dosing in overweight and obese patients with normal ...

These results suggest that in overweight and obese patients, with a normal renal function, a flat carboplatin dose should be administered, ...

Carboplatin Dosing in Overweight and Obese Patients

Normal/ideal body weight: BMI 18.5-24.9 kg/m2; Overweight: BMI 25-29.9 kg/m2; Obese class I: BMI 30-34.9 kg/m2 ...

These results suggest that in overweight and obese patients, with a normal renal function, a flat carboplatin dose should be administered, based ...

Carboplatin dosing in overweight and obese patients with normal ...

These results suggest that in overweight and obese patients, with a normal renal function, a flat carboplatin dose should be administered, based on the ...

The association of body mass index with safety and effectiveness of ...

who showed an average overestimation of carboplatin target AUC of 24.0% (95% confidence interval (CI): 12.9-35.2) in patients with a Body Mass Index (BMI) of ≥ ...

Carboplatin dosing in overweight and obese patients with normal ...

It is suggested that in overweight and obese patients, with a normal renal function, a flat carboplatin dose should be administered, ...

Toxicity and effectiveness of carboplatin in obese or overweight ...

In our study, obese and overweight cancer patients did not show a statistically significant difference in terms of effectiveness and ...

Carboplatin dosing in overweight and obese patients with normal ...

Conclusion: These results suggest that in overweight and obese patients, with a normal renal function, a flat carboplatin dose should be administered, based on ...

Toxicity and effectiveness of carboplatin in obese or overweight ...

In our study, normal-weight patients achieved 85% RDI of carboplatin in a greater proportion than in obese/overweight patients, although it did ...

Antineoplastic dosing in overweight and obese cancer patients

The expert panel recommended full-weight-based chemotherapy doses in the treatment of the obese cancer patient, particularly when cure is the ...

4CPS-114 Dosing of platinum and taxanes in obese patients

For carboplatin, depending on the GFR obtained, this should be limited to a maximum of 150 mL/min or use of an adjusted body weight for dosing. Furthermore, ...

Carboplatin dosing in obese women with ovarian cancer

Obese ovarian cancer patients treated with carboplatin experience substantially less toxicity than normal weight women. The lower toxicity suggests that obese ...

Dosing Chemotherapy in Obese Patients: No Clear Answers, Yet

Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Cancer Chemother Pharmacol. 2009;64:115-122. Epub 2008 ...

Appropriate Systemic Therapy Dosing for Obese Adult Patients With ...

The Panel continues to recommend that full, weight-based cytotoxic chemotherapy doses be used to treat obese adults with cancer.

Toxicity and effectiveness of carboplatin in obese or overweight ...

Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?. Cancer Chemother Pharmacol 2009; 64 ...

Conditioning Chemotherapy Dose Adjustment in Obese Patients

Obese (BMI > 30) (14%) were compared with normal (40%) or elevated BMI [25- 30] (46%). Median follow-up of 24 mo. Dosing: Basis for dosing not reported but. BSA ...

Carboplatin dosing in overweight and obese patients with normal ...

Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? https://doi.org/10.1007/s00280-008-0856-x · Full text.

ASCO Issues New Guideline on Chemotherapy Dosing for Obese ...

... dosing strategies for overweight and obese patients with cancer. The ... carboplatin, should be used for all patients. The complete ...

Carboplatin dosing in overweight and obese patients with normal ...

Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Authors. Ekhart, Corine; Rodenhuis, Sjoerd; Schellens ...

Carboplatin dosing in obese women with ovarian cancer

They found CrCl calculated by the Jelliffe formula leads to an overestimation of carboplatin clearance in patients with a small BMI and an ...